证券代码：000990 证券简称：诚志股份 公告编号：2024-053 诚志股份有限公司（以下简称"公司"）全资子公司上海诚志置业有限公司 （以下简称"诚志置业"）拟将其持有的位于上海浦东新区康桥镇秀沿路 1032-1180（双）号房产（以下简称"标的资产"）以 1386 万元/年的价格对外 出租给昆山润华商业有限公司上海南汇分公司，租赁期限为 2+2 年，即 2 年确定 的租赁期限+2 年待定的租赁期限。 公司于 2024 年 12 月 11 日召开第八届董事会 2024 年第五次临时会议审议通 过了《关于子公司诚志置业对外出租资产的议案》。 本次交易事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 根据《深圳证券交易所股票上市规则》和《公司章程》的有关规定，该事项 无需提交公司股东大会审议。 二、交易各方基本情况 1、出租方 诚志股份有限公司 关于子公司诚志置业对外出租资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次交易概述 公司名称：上海诚志置业有限公司 统一社会信用代码：91350100694398 ...

证券代码：000990 证券简称：诚志股份 公告编号：2024-051 一、同意公司向专业投资者公开发行面值总额不超过 10 亿元科技创新公司 债券的注册申请。 二、本次发行科技创新公司债券应严格按照报送深圳证券交易所的募集说明 书进行。 三、本批复自同意注册之日起 24 个月内有效，公司在注册有效期内可以分 期发行科技创新公司债券。 诚志股份有限公司 关于向专业投资者公开发行科技创新公司债券获得中国证监会 注册批复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 诚志股份有限公司（以下简称"公司"）于近日收到中国证券监督管理委员 会出具的《关于同意诚志股份有限公司向专业投资者公开发行科技创新公司债券 注册的批复》（证监许可〔2024〕1620 号），批复主要内容如下： 2024 年 12 月 4 日 四、自同意注册之日起至本次科技创新公司债券发行结束前，公司如发生重 大事项，应及时报告并按有关规定处理。 公司将严格按照相关法律法规和上述批复文件的要求，在股东大会授权范围 内办理本次发行科技创新公司债券的相关事宜，并及时履行信息披露义务。 诚志股份有限公 ...

证券代码：000990 证券简称：诚志股份 公告编号：2024-050 诚志股份有限公司 关于子公司诚志永清新材料一体化丙烯价值链项目 顺利投产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 诚志股份有限公司（以下简称"公司"）于2023年3月31日召开第八届董事会 2023 年 第二次临时会议，审议通过了《关于子公司诚志永清投资建设新材料一体化丙烯价值链 项目的议案》，拟通过全资子公司南京诚志永清能源科技有限公司（以下简称"诚志永 清"）在南京江北新区新材料科技园投资建设新材料一体化丙烯价值链项目，项目总投 资金额为10.5亿元。具体内容详见公司于2023年4月1日披露的《关于子公司诚志永清投 资建设新材料一体化丙烯价值链项目的公告》（公告编号：2023-022）。 3、新材料领域市场竞争激烈，新的竞争对手不断涌现。如果公司不能持续提升产品 质量和服务水平，可能会在市场竞争中处于劣势。 敬请广大投资者谨慎决策，注意投资风险。 作为"诚志股份2.0"版发展战略的首期收益项目，随着新材料一体化丙烯价值链项 目的顺利投产，公司的产品结构将得到进一步优化。该 ...

Financial Performance - Operating revenue for Q3 2024 was ¥2,576,528,671.05, a decrease of 25.64% year-over-year[2] - Net profit attributable to shareholders was ¥31,322,492.13, down 81.23% compared to the same period last year[2] - Net profit excluding non-recurring gains and losses was ¥23,677,722.08, a decline of 85.90% year-over-year[2] - Basic earnings per share for Q3 2024 was ¥0.0258, down 81.21% from the previous year[2] - Total operating revenue for Q3 2024 was ¥8,237,562,153.58, a decrease of 17.7% compared to ¥10,016,817,075.31 in Q3 2023[13] - Total operating costs for Q3 2024 were ¥7,744,903,559.52, down from ¥9,619,387,978.81 in the same period last year, reflecting a reduction of 19.5%[13] - The net profit for Q3 2024 was CNY 301,992,109.07, an increase of 36.2% compared to CNY 221,655,203.65 in the same period last year[14] - The total profit amounted to CNY 422,709,695.85, up from CNY 285,740,226.37, reflecting a growth of 48.0% year-over-year[14] - Operating profit reached CNY 423,827,439.50, compared to CNY 301,142,116.57 in Q3 2023, marking a 40.7% increase[14] - The total comprehensive income for the period was CNY 301,695,971.89, compared to CNY 222,108,415.82 in Q3 2023, indicating a growth of 35.8%[14] - Earnings per share (EPS) for the quarter was CNY 0.1798, up from CNY 0.1076 in the same period last year[14] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥1,161,086,778.30, an increase of 26.94% year-to-date[2] - Cash inflow from investment activities increased by 47.46% to ¥4,428,934,266.75, primarily due to an increase in the redemption of current financial investments[6] - Cash outflow from investment activities surged by 95.58% to ¥6,296,469,045.15, mainly due to increased project investments and current financial investments[6] - Net cash flow from investment activities was negative at ¥-1,867,534,778.40, a significant increase of 764.59% compared to ¥-216,001,880.38 last year[6] - Cash inflow from financing activities rose by 30.80% to ¥4,181,552,851.31, driven by increased issuance of corporate bonds and bank loans[6] - Net cash flow from financing activities increased by 494.65% to ¥398,313,851.52, attributed to new loans and the issuance of corporate medium-term notes[6] - Cash flow from operating activities generated CNY 1,161,086,778.30, an increase of 27.0% from CNY 914,641,835.56 in the previous year[15] - Cash flow from investment activities showed a net outflow of CNY 1,867,534,778.40, worsening from a net outflow of CNY 216,001,880.38 in the same quarter last year[15] - Cash flow from financing activities resulted in a net inflow of CNY 398,313,851.52, compared to a net outflow of CNY 100,928,511.86 in Q3 2023[15] Assets and Liabilities - Total assets increased to ¥26,804,237,087.91, representing a growth of 4.12% from the end of the previous year[2] - The company’s total liabilities increased by 46.86% due to increased financing activities[4] - The company’s long-term borrowings rose by 74.54% to ¥1,150,559,674.25, primarily due to new bank loans[4] - The total current assets increased to ¥7,004,422,400.70 from ¥6,362,213,631.06, representing a growth of about 10.1%[10] - Total liabilities reached ¥8,093,658,490.36 in Q3 2024, an increase from ¥7,280,190,487.54 in Q3 2023, representing a rise of 11.1%[12] - The company's total equity amounted to ¥18,710,578,597.55 in Q3 2024, up from ¥18,463,185,577.11 in Q3 2023, reflecting an increase of 1.3%[12] - Non-current assets totaled ¥19,799,814,687.21 as of Q3 2024, compared to ¥19,381,162,433.59 at the end of Q3 2023, indicating a growth of 2.2%[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,474[7] - The largest shareholder, Chengzhi Kairun Holdings, holds 30.83% of the shares, totaling 374,650,564 shares[7] - The second-largest shareholder, Tianfu Qingyuan Holdings, owns 15.77% of the shares, amounting to 191,677,639 shares[7] Projects and Developments - The company has completed the construction of the new material integrated propylene value chain project with a total investment of ¥1.05 billion, and is currently preparing for trial production[9] - The company is in the process of establishing a health insurance company with a planned registered capital of ¥1 billion, although there has been no progress reported as of this period[8] - The company has initiated the IPO preparation for its subsidiary, Chengzhi Yonghua, with ongoing due diligence work[8] - The company has invested approximately ¥350 million in the high-performance liquid crystal materials industry upgrade project, with the feasibility study report completed[9] - The company has received a refund of ¥2,399,200 related to the cancellation of the liquid crystal materials project, with ¥2 million already paid[8] - The company has completed the construction of the multifunctional workshop and raw material workshop project in Yingtan, with an expected total investment of ¥350 million[9] - The company is negotiating a repayment plan with Wansheng Bio, with an agreement reached for installment payments totaling ¥133,178,783.74 plus penalties[9] - The company has completed the construction of the POE project and ultra-high molecular weight polyethylene project, with necessary permits obtained[8] Cash and Cash Equivalents - Cash and cash equivalents decreased by 41.71% to ¥62,871,694.00 from ¥107,863,096.46 year-on-year[6] - The company's cash and cash equivalents decreased to ¥2,016,424,931.27 from ¥2,407,480,358.55, reflecting a decline of approximately 16.2%[10] - The company's cash and cash equivalents at the end of the period stood at CNY 1,951,414,527.38, slightly up from CNY 1,910,448,084.48 at the end of Q3 2023[16] - The cash and cash equivalents decreased to ¥3,003,748,849.16 in Q3 2024 from ¥2,990,427,708.27 in Q3 2023, showing a slight increase of 0.7%[11]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [3][17]. Core Views - The company reported a revenue of 5.66 billion yuan in the first half of 2024, a year-on-year decrease of 13.6%, but achieved a net profit of 187 million yuan, marking a turnaround from losses [2]. - The company is experiencing a weak recovery in downstream demand, leading to a downward adjustment in profit forecasts for 2024-2025, with net profits expected to be 288 million yuan, 344 million yuan, and 404 million yuan for 2024, 2025, and 2026 respectively [3]. - The company is advancing its "one body, two wings" strategy and is accelerating the layout of new production capacity, which is expected to support future growth [3]. Financial Performance - In Q2 2024, the company achieved a revenue of 2.94 billion yuan, a year-on-year decrease of 7.7%, but a quarter-on-quarter increase of 8.0%, with a net profit of 33 million yuan, reflecting a year-on-year increase of 58.8% [2]. - The average market prices for key clean energy products in the first half of 2024 were as follows: ethylene at 961 USD/ton (up 6.9%), propylene at 6887 yuan/ton (down 2.7%), and n-butanol at 8374 yuan/ton (up 10.6%) [7]. - The company’s cost of raw materials, including non-caking coal and thermal coal, decreased by 30% and 1% respectively, contributing to improved profitability [7]. Strategic Developments - The company has signed a technology package for the POE project, which is progressing steadily, with a total investment of approximately 4 billion yuan and a construction period of three years [8]. - The acquisition of 1183 patent assets for 240 million yuan is expected to enhance the competitiveness of the company's liquid crystal materials segment [15]. - The company has also secured land use rights for 154,200 square meters in Nanjing, further expanding its clean energy business [15].

公司于 2024 年 6 月 15 日披露了《关于收到中国银行间市场交易商协会<接 受注册通知书>的公告》（公告编号：2024-039），中国银行间市场交易商协会 出具《接受注册通知书》（以下简称"通知书"）决定接受公司中期票据注册， 注册金额为 20 亿元，注册额度自通知书落款之日起 2 年内有效，由招商银行股 份有限公司主承销。 证券代码：000990 证券简称：诚志股份 公告编号：2024-048 诚志股份有限公司 关于2024年度第一期中期票据（品种一）发行结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 诚志股份有限公司（以下简称"公司"或"本公司"）第七届董事会第二十 一次会议、2021 年年度股东大会审议通过了《关于公司申请注册发行中期票据 的议案》，同意公司向中国银行间市场交易商协会申请注册发行总额不超过人民 币 20 亿元（含人民币 20 亿元）的中期票据。具体内容详见公司于 2022 年 4 月 20 日披露的《关于拟申请注册发行中期票据的公告》（公告编号：2022-017）。 公 司 有 关 本 次 中 期 票 据 发 行 的 ...

证券代码：000990 证券简称：诚志股份 公告编号：2024-045 一、监事会会议召开情况 诚志股份有限公司 第八届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、会议通知时间与方式 诚志股份有限公司（以下简称"公司"）第八届监事会第九次会议通知于 2024 年 7 月 11 日以书面方式送达全体监事。 2、会议召开的时间、方式和表决情况 （1）会议时间：2024 年 7 月 24 日上午 （2）召开地点：北京市海淀区清华科技园创新大厦 B 座诚志股份北京管理 总部会议室 （3）召开方式：以现场方式召开 （4）主持人：监事会主席朱玉杰先生 （5）监事出席会议情况：应表决监事 3 人，实际表决监事 3 人 本次会议符合《公司法》和《公司章程》等有关规定，所作的决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 表决结果：3 票同意、0 票反对、0 票弃权。 2、审议通过《关于公司核销部分债权资产的议案》 经审核，监事会认为：公司依据《企业会计准则》及公司会计政策要求核销 债权 ...

证券代码：000990 证券简称：诚志股份 公告编号：2024-047 诚志股份有限公司 关于2024年上半年度计提资产减值准备及核销资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 诚志股份有限公司（以下简称"公司"）于 2024 年 7 月 24 日召开的第八届 董事会第九次会议、第八届监事会第九次会议审议通过了《关于公司 2024 年上 半年计提资产减值准备的议案》和《关于公司核销部分债权资产的议案》。上述 事项无需提交公司股东大会审议。现将公司 2024 年上半年度计提资产减值准备 及核销部分债权资产的具体情况公告如下： 一、本次计提资产减值准备的情况 根据《企业会计准则》、《深圳证券交易所股票上市规则》的规定和要求， 为更加真实、准确地反映公司 2024 年 6 月 30 日的资产价值和财务状况，公司对 合并范围内各类资产进行了全面的清查，基于谨慎性原则，根据公司管理层的提 议，拟对部分资产计提减值准备，具体情况如下： 单位：万元 | 项 目 | | 信用减值准备 | 资产减值准备 | 合计 | | --- | --- | --- | -- ...

证券代码：000990 证券简称：诚志股份 公告编号：2024-044 诚志股份有限公司 第八届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、会议通知时间与方式 诚志股份有限公司（以下简称"公司"）第八届董事会第九次会议通知于 2024 年 7 月 11 日以书面通知方式送达全体董事。 2、会议召开的时间、地点和方式 （1）会议时间：2024 年 7 月 24 日上午 10:00 （2）召开地点：北京市海淀区清华科技园创新大厦 B 座诚志股份北京管理 总部会议室 （3）召开方式：以现场方式召开 （4）董事出席会议情况：应到董事 7 人，实到 7 人 （5）主持人：董事长龙大伟先生 （6）列席人员：监事及部分高级管理人员 本次会议符合《公司法》和《公司章程》等有关规定，所作的决议合法有效。 二、董事会会议审议情况 表决结果：7 票同意、0 票反对、0 票弃权。 2、审议通过《关于公司核销部分债权资产的议案》 根据《企业会计准则》及公司会计政策等相关规定，为真实、准确地反映公 司财务状况，按照"依法合规、规范 ...

诚志股份有限公司2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 诚志股份有限公司2024年半年度非经营性资金占用及其他关联资金往来情况汇总表（续） 单位：万元 | 其他关联 | | 往来方与上市公司 | 上市公司核算 | 2024年期初往来 | 2024年半年度往 | 2024年半年度偿 | 2024年6月30日 | | 往来性质（经营 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金往来 | 资金往来方名称 | 的关联关系 | 的会计科目 | 资金余额 | 来累计发生金额 | 还累计发生金额 | 往来资金余额 | 往来形成原因 | 性往来、非经营 性往来） | | 控股股东、实际 控制人及其附属 | | | | | | | | | | | 企业 | 安徽诚志显示玻璃有限公司 | 控股子公司 | 其他应收款 | 6,750.00 | 2,947.42 | 689.67 | 9,007.75 | 资金拆借 | 非经营性往来 | | | 诚志生命科技有限公司 | 控股子公司 | 其他应收款 | 19, ...